CPT-11 (Irinotecan): Difference between revisions
(Created page with "{{TreatmentInfo |drug_name=CPT-11 (Irinotecan) |FDA_approval=Approved for the treatment of colon cancer; under investigation for recurrent glioma |used_for=Recurrent Glioblastoma Multiforme (GBM) and other malignant gliomas |clinical_trial_phase=Phase I/II trials in combination with other therapies |common_side_effects=Hematologic, gastrointestinal, and hepatic toxicities noted; acceptable safety profile in combination regimens |OS_without=Not directly specified; histori...") |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
Line 14: | Line 14: | ||
|toxicity_explanation=While showing promise in efficacy, the combination treatments involving CPT-11 have been associated with manageable but significant toxicities, including hematologic, gastrointestinal, and hepatic adverse events. | |toxicity_explanation=While showing promise in efficacy, the combination treatments involving CPT-11 have been associated with manageable but significant toxicities, including hematologic, gastrointestinal, and hepatic adverse events. | ||
|book_text=Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas. | |book_text=Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas. | ||
| | |treatment_category=Other chemotherapy agents at recurrence | ||
}} | }} |
Latest revision as of 10:42, 12 November 2024
From Ben Williams Book: Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas.Property "Has original text" (as page type) with input value "Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.